Clinical trial
A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients…
NCT00396565 · Janssen Pharmaceutical K.K., Industry · Completed
Key facts
| NCT number | NCT00396565 |
|---|---|
| Title | A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia |
| Official title | A Placebo-Controlled Double Blind Comparative Study of JNS007ER in Patients With Schizophrenia |
| Lead sponsor | Janssen Pharmaceutical K.K., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | ER OROS paliperidone, Placebo, Olanzapine |
| Enrollment | 394 |
| Start date | Jul 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Nov 7, 2006 |
| Last update posted | Apr 29, 2014 |
| Countries | Japan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: